Sichuan Huiyu Pharmaceutical Co (SHSE:688553) Piotroski F-Score: 4 (As of Jul. 28, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688553 Sichuan Huiyu Pharmaceutical Co Ltd SHSE:688553
65 GF Score
Price ¥10.27
GF Value ¥9.85
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Sichuan Huiyu Pharmaceutical Co Piotroski F-Score?

Sichuan Huiyu Pharmaceutical Co SHSE:688553 -2.00% 65 Piotroski F-Score is 4 as of Jul. 28, 2026, which is at its 10-year median of 4.00. GuruFocus rates SHSE:688553 with a GF Score™ of 65/100 and a GF Value™ of ¥9.85 (Fairly Valued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Sichuan Huiyu Pharmaceutical Co ranks worse than 61.37% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sichuan Huiyu Pharmaceutical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SHSE:688553' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 4

During the past 9 years, the highest Piotroski F-Score of Sichuan Huiyu Pharmaceutical Co was 6. The lowest was 2. And the median was 4.

Sichuan Huiyu Pharmaceutical Co  (SHSE:688553) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sichuan Huiyu Pharmaceutical Co Piotroski F-Score Related Terms


Sichuan Huiyu Pharmaceutical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Huiyu Pharmaceutical Co Piotroski F-Score Chart

Sichuan Huiyu Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 5.00 3.00 4.00 5.00 4.00

Sichuan Huiyu Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 5.00 4.00 4.00

SHSE:688553 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Huiyu Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score falls into.


SHSE:688553
65GF Score
Sichuan Huiyu Pharmaceutical Co Ltd SHSE:688553
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -55.094 + 29.916 + 25.843 + 21.869 = ¥23 Mil.
Cash Flow from Operations was -29.628 + 58.234 + 59.345 + 20.167 = ¥108 Mil.
Revenue was 214.066 + 288.632 + 256.395 + 269.207 = ¥1,028 Mil.
Gross Profit was 159.9 + 237.245 + 197.511 + 213.147 = ¥808 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(4949.444 + 4835.724 + 4876.238 + 5019.499 + 5128.572) / 5 = ¥4961.8954 Mil.
Total Assets at the begining of this year (Mar25) was ¥4,949 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Total Current Assets was ¥3,300 Mil.
Total Current Liabilities was ¥1,265 Mil.
Net Income was 18.778 + 162.139 + 98.038 + -25.626 = ¥253 Mil.

Revenue was 289.598 + 319.642 + 242.538 + 239.053 = ¥1,091 Mil.
Gross Profit was 236.043 + 270.417 + 204.542 + 199.894 = ¥911 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(4808.882 + 4711.316 + 5049.192 + 5165.627 + 4949.444) / 5 = ¥4936.8922 Mil.
Total Assets at the begining of last year (Mar24) was ¥4,809 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Total Current Assets was ¥3,152 Mil.
Total Current Liabilities was ¥925 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sichuan Huiyu Pharmaceutical Co's current Net Income (TTM) was 23. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sichuan Huiyu Pharmaceutical Co's current Cash Flow from Operations (TTM) was 108. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=22.534/4949.444
=0.00455283

ROA (Last Year)=Net Income/Total Assets (Mar24)
=253.329/4808.882
=0.0526794

Sichuan Huiyu Pharmaceutical Co's return on assets of this year was 0.00455283. Sichuan Huiyu Pharmaceutical Co's return on assets of last year was 0.0526794. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sichuan Huiyu Pharmaceutical Co's current Net Income (TTM) was 23. Sichuan Huiyu Pharmaceutical Co's current Cash Flow from Operations (TTM) was 108. ==> 108 > 23 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/4961.8954
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/4936.8922
=0

Sichuan Huiyu Pharmaceutical Co's gearing of this year was 0. Sichuan Huiyu Pharmaceutical Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=3300.02/1264.771
=2.6091838

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3151.506/924.602
=3.40850009

Sichuan Huiyu Pharmaceutical Co's current ratio of this year was 2.6091838. Sichuan Huiyu Pharmaceutical Co's current ratio of last year was 3.40850009. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sichuan Huiyu Pharmaceutical Co's number of shares in issue this year was 647.327. Sichuan Huiyu Pharmaceutical Co's number of shares in issue last year was 632.12. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=807.803/1028.3
=0.78557133

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=910.896/1090.831
=0.83504778

Sichuan Huiyu Pharmaceutical Co's gross margin of this year was 0.78557133. Sichuan Huiyu Pharmaceutical Co's gross margin of last year was 0.83504778. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1028.3/4949.444
=0.20776071

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1090.831/4808.882
=0.22683672

Sichuan Huiyu Pharmaceutical Co's asset turnover of this year was 0.20776071. Sichuan Huiyu Pharmaceutical Co's asset turnover of last year was 0.22683672. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sichuan Huiyu Pharmaceutical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Sichuan Huiyu Pharmaceutical Co (SHSE:688553) has a Piotroski F-Score of 4 as of Jul. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. This is near median its historical median of 4.00. Over the past decade, Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #602 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score too high?
Sichuan Huiyu Pharmaceutical Co's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Sichuan Huiyu Pharmaceutical Co's value of 4 is 20% below this industry median. Based on the distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #602 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sichuan Huiyu Pharmaceutical Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Huiyu Pharmaceutical Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #602 out of 981 companies for Piotroski F-Score. This places Sichuan Huiyu Pharmaceutical Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Sichuan Huiyu Pharmaceutical Co's value of 4 is 20% below this benchmark. Historically, Sichuan Huiyu Pharmaceutical Co's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Sichuan Huiyu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Huiyu Pharmaceutical Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Huiyu Pharmaceutical Co's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Huiyu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co (SHSE:688553) is currently considered Fairly Valued. The stock's GF Value™ is ¥9.85, compared to a current price of ¥10.27 — trading 4.3% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Drug Manufacturers industry median of 5.00. Sichuan Huiyu Pharmaceutical Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sichuan Huiyu Pharmaceutical Co (SHSE:688553), the current Piotroski F-Score is 4 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Huiyu Pharmaceutical Co (SHSE:688553) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥10.27 is trading 4.3% above its estimated GF Value™ of ¥9.85. GuruFocus considers Sichuan Huiyu Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:688553:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: ¥9.85 vs. price of ¥10.27 (4.3% above fair value)
  • GF Score™: 65/100 with 6 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#602 of 981)

No single metric tells the full story. See the SHSE:688553 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sichuan Huiyu Pharmaceutical Co Business Description

Address No.333 Hanyang Road, Building 3, Shizhong District, Sichuan Province, Neijiang, CHN, 641000
Sichuan Huiyu Pharmaceutical Co Ltd is engaged in the research and development, production and sales of anti-tumor and injection drugs.
65GF Score

Get the complete analysis for SHSE:688553

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.27
Price
¥9.85
GF Value